keyword
https://read.qxmd.com/read/38704338/epidemiology-and-management-of-patients-with-kidney-disease-and-heart-failure-with-preserved-ejection-fraction
#1
REVIEW
Marcelle L Tuttle, James C Fang, Mark J Sarnak, Wendy McCallum
Heart failure with preserved ejection fraction (HFpEF) comprises approximately one-half of all diagnoses of heart failure. There is significant overlap of this clinical syndrome with chronic kidney disease (CKD), with many shared comorbid conditions. The presence of CKD in patients with HFpEF is one of the most powerful risk factors for adverse clinical outcomes, including death and heart failure hospitalization. The pathophysiology linking HFpEF and CKD remains unclear, but it is postulated to consist of numerous bidirectional pathways, including endothelial dysfunction, inflammation, obesity, insulin resistance, and impaired sodium handling...
May 3, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38704332/exploring-changes-in-myocyte-structure-contractility-and-energetics-from-mechanical-unloading-in-patients-with-heart-failure-undergoing-ventricular-assist-device-implantation-a-systematic-review-and-meta-analysis
#2
REVIEW
Patrick Tran, Clement Lau, Mithilesh Joshi, Michael Kuehl, Helen Maddock, Prithwish Banerjee
AIMS: Recent reports of myocardial recovery after mechanical unloading with left ventricular assist devices (LVADs) have challenged the prevailing notion that end-stage heart failure (HF) is irreversible. To improve our understanding of this phenomenon, we comprehensively analysed the structural, functional, and energetic changes in failing human cardiomyocytes after LVAD implantation. METHODS: Based on a prospectively registered protocol (PROSPERO-CRD42022380214), 30 eligible studies were identified from 940 records with a pooled population of 648 patients predominantly with non-ischaemic cardiomyopathy...
May 3, 2024: Heart, Lung & Circulation
https://read.qxmd.com/read/38702356/dynamic-molecular-signatures-of-acute-myocardial-infarction-based-on-transcriptomics-and-metabolomics
#3
JOURNAL ARTICLE
Xuejiao Wang, Guang Yang, Jun Li, Chao Meng, Zengming Xue
Acute myocardial infarction (AMI) commonly precedes ventricular remodeling, heart failure. Few dynamic molecular signatures have gained widespread acceptance in mainstream clinical testing despite the discovery of many potential candidates. These unmet needs with respect to biomarker and drug discovery of AMI necessitate a prioritization. We enrolled patients with AMI aged between 30 and 70. RNA-seq analysis was performed on the peripheral blood mononuclear cells collected from the patients at three time points: 1 day, 7 days, and 3 months after AMI...
May 3, 2024: Scientific Reports
https://read.qxmd.com/read/38701513/cytochrome-p450-1b1-is-critical-in-the-development-of-tnf-%C3%AE-il-6-and-lps-induced-cellular-hypertrophy
#4
JOURNAL ARTICLE
Mohamed A W Elkhatib, Samar H Gerges, Fadumo A Isse, Ayman Os El-Kadi
Heart failure (HF) is preceded by cellular hypertrophy (CeH) which alters expression of cytochrome P450 enzymes (CYPs) and arachidonic acid (AA) metabolism. Inflammation is involved in CeH pathophysiology, but mechanisms remain elusive. This study investigates the impacts of TNF-α, IL-6, and LPS on the development of CeH and the role of CYP1B1. AC16 cells were treated with TNF-α, IL-6, and LPS in the presence and absence of CYP1B1-siRNA or resveratrol. mRNA and protein expression levels of CYP1B1 and hypertrophic markers were determined using PCR and Western blot analysis, respectively...
May 3, 2024: Canadian Journal of Physiology and Pharmacology
https://read.qxmd.com/read/38700861/irregular-cycles-ovulatory-disorders-and-cardiometabolic-conditions-in-a-us-based-digital-cohort
#5
JOURNAL ARTICLE
Zifan Wang, Anne Marie Z Jukic, Donna D Baird, Allen J Wilcox, Huichu Li, Christine L Curry, Tyler Fischer-Colbrie, Jukka-Pekka Onnela, Michelle A Williams, Russ Hauser, Brent A Coull, Shruthi Mahalingaiah
IMPORTANCE: Polycystic ovary syndrome (PCOS), characterized by irregular menstrual cycles and hyperandrogenism, is a common ovulatory disorder. Having an irregular cycle is a potential marker for cardiometabolic conditions, but data are limited on whether the associations differ by PCOS status or potential interventions. OBJECTIVE: To evaluate the association of PCOS, time to regularity since menarche (adolescence), and irregular cycles (adulthood) with cardiometabolic conditions...
May 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38699780/the-sclerotic-component-of-metabolic-syndrome-fibroblast-activities-may-be-the-central-common-denominator-driving-organ-function-loss-and-death
#6
REVIEW
Alexander Lynge Reese-Petersen, Signe Holm Nielsen, Jannie Marie Bülow Sand, Jörn M Schattenberg, Elisabetta Bugianesi, Morten A Karsdal
Fibrosis is a common feature of more than 50 different diseases and the cause of more than 35% of deaths worldwide, of which liver, kidney, skin, heart and, recently, lungs are receiving the most attention. Tissue changes, resulting in loss of organ function, are both a cause and consequence of disease and outcome. Fibrosis is caused by an excess deposition of extracellular matrix proteins, which over time results in impaired organ function and organ failure, and the pathways leading to increased fibroblast activation are many...
May 3, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38699311/ptsd-comorbidities-gender-and-increased-risk-of-cardiovascular-disease-in-a-large-military-cohort
#7
David S Krantz, Frances H Gabbay, Elizabeth A Belleau, Pablo A Aliaga, Gary H Wynn, Murray B Stein, Robert J Ursano, James A Naifeh
IMPORTANCE: Posttraumatic stress disorder (PTSD) is a prevalent mental health problem that increases risk of cardiovascular disease (CVD). It is not known whether gender or comorbidities modify associations between PTSD and CVD. OBJECTIVE: To assess risk of hypertension and atherosclerotic CVD (ASCVD) associated with PTSD in a predominantly young military population, and determine if gender or PTSD comorbidities modify these associations. DESIGN SETTING AND PARTICIPANTS: Using administrative medical records, this longitudinal, retrospective cohort study assessed relationships of PTSD, gender, comorbidities (metabolic risk factors [MRF], behavioral risk factors [BRF], depression, and sleep disorders) to subsequent hypertension and ASCVD among 863,993 active-duty U...
April 15, 2024: medRxiv
https://read.qxmd.com/read/38698563/hyperlactataemia-is-a-marker-of-reduced-exercise-capacity-in-heart-failure-with-preserved-ejection-fraction
#8
JOURNAL ARTICLE
Emilia Nan Tie, Emil Wolsk, Shane Nanayakkara, Donna Vizi, Justin Mariani, Jacob Eifer Moller, Christian Hassager, Finn Gustafsson, David M Kaye
AIMS: Heart failure with preserved ejection fraction (HFpEF) is associated with an array of central and peripheral haemodynamic and metabolic changes. The exact pathogenesis of exercise limitation in HFpEF remains uncertain. Our aim was to compare lactate accumulation and central haemodynamic responses to exercise in patients with HFpEF, non-cardiac dyspnoea (NCD), and healthy volunteers. METHODS AND RESULTS: Right heart catheterization with mixed venous blood gas and lactate measurements was performed at rest and during symptom-limited supine exercise...
May 2, 2024: ESC Heart Failure
https://read.qxmd.com/read/38694929/vitamin-d-deficiency-in-patients-hospitalized-for-heart-failure-living-in-the-tropics
#9
JOURNAL ARTICLE
Lucian Batista de Oliveira, Mariana Andrade de Figueiredo Martins Siqueira, Rafael Buarque de Macedo Gadêlha, Jessica Garcia, Francisco Bandeira
BACKGROUND AND OBJECTIVES: Vitamin D, as a steroid hormone, has multiple effects on human body and its deficiency has been associated with an increased risk of heart failure (HF) and unfavorable outcomes. The present study investigated the prevalence of vitamin D deficiency (VDD) and its relationship with cardiometabolic parameters in patients hospitalized for HF living in the city of Recife (latitude 8° South). METHODS: Analytical cross-sectional study, with men and women aged 40-64 years...
April 2024: International journal of heart failure
https://read.qxmd.com/read/38694924/mitochondria-associated-endoplasmic-reticulum-membranes-as-a-therapeutic-target-for-cardiovascular-diseases
#10
REVIEW
Yanqiu Ding, Nanyang Liu, Dawu Zhang, Lijun Guo, Qinghua Shang, Yicheng Liu, Gaocan Ren, Xiaochang Ma
Cardiovascular diseases (CVDs) are currently the leading cause of death worldwide. In 2022, the CVDs contributed to 19.8 million deaths globally, accounting for one-third of all global deaths. With an aging population and changing lifestyles, CVDs pose a major threat to human health. Mitochondria-associated endoplasmic reticulum membranes (MAMs) are communication platforms between cellular organelles and regulate cellular physiological functions, including apoptosis, autophagy, and programmed necrosis. Further research has shown that MAMs play a critical role in the pathogenesis of CVDs, including myocardial ischemia and reperfusion injury, heart failure, pulmonary hypertension, and coronary atherosclerosis...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38694298/unlocking-the-gut-heart-axis-exploring-the-role-of-gut-microbiota-in-cardiovascular-health-and-disease
#11
REVIEW
Sanobar Shariff, Alicia Kwan Su Huey, Nishant Parag Soni, Amer Yahia, Doha Hammoud, Abubakar Nazir, Olivier Uwishema, Magda Wojtara
INTRODUCTION: Gut microbiota has emerged as a pivotal player in cardiovascular health and disease, extending its influence beyond the gut through intricate metabolic processes and interactions with the immune system. Accumulating evidence supports a significant association between gut microbiota and cardiovascular diseases such as atherosclerosis, hypertension, and heart failure. Dietary patterns have been identified as key factors shaping the composition of the gut microbiota and exerting notable impacts on cardiovascular health...
May 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38693484/obesity-and-metabolic-syndrome-in-patients-with-heart-failure-with-preserved-ejection-fraction-a-cross-sectional-analysis-of-the-veradigm-cardiology-registry
#12
JOURNAL ARTICLE
Jay P Bae, Lee Kallenbach, David R Nelson, Kevin Lavelle, Jessamine P Winer-Jones, Machaon Bonafede, Masahiro Murakami
BACKGROUND: The proportion of heart failure patients with preserved ejection fraction has been rising over the past decades and has coincided with increases in the prevalence of obesity and metabolic syndrome. The relationship between these interconnected comorbidities and heart failure with preserved ejection fraction (HFpEF) is still poorly understood. This study characterized obesity and metabolic syndrome among real-world patients with HFpEF. METHODS: We identified adults with heart failure in the Veradigm Cardiology Registry, previously the PINNACLE Registry, with a left ventricular ejection fraction measurement ≥ 50% between 01/01/2016 and 12/31/2019...
May 1, 2024: BMC Endocrine Disorders
https://read.qxmd.com/read/38693202/transcriptome-analysis-of-cardiac-endothelial-cells-after-myocardial-infarction-reveals-temporal-changes-and-long-term-deficits
#13
JOURNAL ARTICLE
Chitra Basu, Presley L Cannon, Cassandra P Awgulewitsch, Cristi L Galindo, Eric R Gamazon, Antonis K Hatzopoulos
Endothelial cells (ECs) have essential roles in cardiac tissue repair after myocardial infarction (MI). To establish stage-specific and long-term effects of the ischemic injury on cardiac ECs, we analyzed their transcriptome at landmark time points after MI in mice. We found that early EC response at Day 2 post-MI centered on metabolic changes, acquisition of proinflammatory phenotypes, initiation of the S phase of cell cycle, and activation of stress-response pathways, followed by progression to mitosis (M/G2 phase) and acquisition of proangiogenic and mesenchymal properties during scar formation at Day 7...
May 1, 2024: Scientific Reports
https://read.qxmd.com/read/38691671/the-ketogenic-diet-does-not-improve-cardiac-function-and-blunts-glucose-oxidation-in-ischemic-heart-failure
#14
JOURNAL ARTICLE
Kim L Ho, Qutuba Karwi, Faqi Wang, Cory Wagg, Liyan Zhang, Sai Panidarapu, Brandon Chen, Simran Pherwani, Amanda A Greenwell, Gavin Oudit, John R Ussher, Gary D Lopaschuk
AIMS: Cardiac energy metabolism is perturbed in ischemic heart failure and is characterized by a shift from mitochondrial oxidative metabolism to glycolysis. Notably, the failing heart relies more on ketones for energy than a healthy heart, an adaptive mechanism that improves the energy-starved status of the failing heart. However, whether this can be implemented therapeutically remains unknown. Therefore, our aim was to determine if increasing ketone delivery to the heart via a ketogenic diet can improve the outcomes of heart failure...
May 1, 2024: Cardiovascular Research
https://read.qxmd.com/read/38689163/sirt6-in-regulation-of-mitochondrial-damage-and-associated-cardiac-dysfunctions-a-possible-therapeutic-target-for-cvds
#15
REVIEW
K P Divya, Navjot Kanwar, P V Anuranjana, Gautam Kumar, Fathima Beegum, Krupa Thankam George, Nitesh Kumar, K Nandakumar, Abhinav Kanwal
Cardiovascular diseases (CVDs) can be described as a global health emergency imploring possible prevention strategies. Although the pathogenesis of CVDs has been extensively studied, the role of mitochondrial dysfunction in CVD development has yet to be investigated. Diabetic cardiomyopathy, ischemic-reperfusion injury, and heart failure are some of the CVDs resulting from mitochondrial dysfunction Recent evidence from the research states that any dysfunction of mitochondria has an impact on metabolic alteration, eventually causes the death of a healthy cell and therefore, progressively directing to the predisposition of disease...
April 30, 2024: Cardiovascular Toxicology
https://read.qxmd.com/read/38686853/short-chain-fatty-acid-butyrate-is-an-inotropic-agent-with-vasorelaxant-and-cardioprotective-properties
#16
JOURNAL ARTICLE
Jacob Marthinsen Seefeldt, Casper Homilius, Jakob Hansen, Thomas Ravn Lassen, Nichlas Riise Jespersen, Rebekka Vibjerg Jensen, Ebbe Boedtkjer, Hans Erik Bøtker, Roni Nielsen
BACKGROUND: The heart can metabolize the microbiota-derived short-chain fatty acid butyrate. Butyrate may have beneficial effects in heart failure, but the underlying mechanisms are unknown. We tested the hypothesis that butyrate elevates cardiac output by mechanisms involving direct stimulation of cardiac contractility and vasorelaxation in rats. METHODS AND RESULTS: We examined the effects of butyrate on (1) in vivo hemodynamics using parallel echocardiographic and invasive blood pressure measurements, (2) isolated perfused hearts in Langendorff systems under physiological conditions and after ischemia and reperfusion, and (3) isolated coronary arteries mounted in isometric wire myographs...
April 30, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38684702/metabolomic-insights-in-advanced-cardiomyopathy-of-chronic-chagasic-and-idiopathic-patients-that-underwent-heart-transplant
#17
JOURNAL ARTICLE
Raphaela M de Oliveira, Mariana U B Paiva, Carolina R C Picossi, Diego V N Paiva, Carlos A O Ricart, Francisco J Ruperez, Coral Barbas, Fernando A Atik, Aline M A Martins
Heart failure (HF) studies typically focus on ischemic and idiopathic heart diseases. Chronic chagasic cardiomyopathy (CCC) is a progressive degenerative inflammatory condition highly prevalent in Latin America that leads to a disturbance of cardiac conduction system. Despite its clinical and epidemiological importance, CCC molecular pathogenesis is poorly understood. Here we characterize and discriminate the plasma metabolomic profile of 15 patients with advanced HF referred for heart transplantation - 8 patients with CCC and 7 with idiopathic dilated cardiomyopathy (IDC) - using gas chromatography/quadrupole time-of-flight mass spectrometry...
April 29, 2024: Scientific Reports
https://read.qxmd.com/read/38679957/implications-and-hidden-toxicity-of-cardiometabolic-syndrome-and-early-stage-heart-failure-in-carfilzomib-induced-cardiotoxicity
#18
JOURNAL ARTICLE
Panagiotis Efentakis, Aimilia Varela, Sofia Lamprou, Eleni-Dimitra Papanagnou, Michail Chatzistefanou, Andriana Christodoulou, Constantinos H Davos, Maria Gavriatopoulou, Ioannis Trougakos, Meletios Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou
BACKGROUND AND PURPOSE: Cancer therapy-related cardiovascular adverse events (CAEs) in presence of comorbidities, are in the spotlight of the cardio-oncology guidelines. Carfilzomib (Cfz), indicated for relapsed/refractory multiple myeloma (MM), presents with serious CAEs. MM is often accompanied with co-existing comorbidities. However, Cfz use in MM patients with cardiometabolic syndrome (CMS) or in heart failure with reduced ejection fraction (HFrEF), is questionable. EXPERIMENTAL APPROACH: ApoE-/- and C57BL6/J male mice received 14 weeks Western Diet (WD) (CMS models)...
April 28, 2024: British Journal of Pharmacology
https://read.qxmd.com/read/38679211/overexpression-of-soluble-epoxide-hydrolase-reduces-post-ischemic-recovery-of-cardiac-contractile-function
#19
JOURNAL ARTICLE
Matthew L Edin, Artiom Gruzdev, J Alyce Bradbury, Joan P Graves, Ginger W Muse, David R Goulding, Fred B Lih, Laura M DeGraff, Darryl C Zeldin
Cytochromes P450 can metabolize endogenous fatty acids, such as arachidonic acid, to bioactive lipids such as epoxyeicosatrienoic acids (EETs) that have beneficial effects. EETs protect hearts against ischemic damage, heart failure or fibrosis; however, their effects are limited by hydrolysis to less active dihydroxy oxylipins by soluble epoxide hydrolase (sEH), encoded by the epoxide hydrolase 2 gene (EPHX2, EC 3.3.2.10). Pharmacological inhibition or genetic disruption of sEH/EPHX2 have been widely studied for their impact on cardiovascular diseases...
April 26, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38678962/cardiovascular-outcomes-and-molecular-targets-for-the-cardiac-effects-of-sodium-glucose-cotransporter-2-inhibitors-a-systematic-review
#20
REVIEW
Rosalinda Madonna, Filippo Biondi, Mattia Alberti, Sandra Ghelardoni, Letizia Mattii, Alberto D'Alleva
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new class of glucose-lowering drugs traditionally used to control blood glucose levels in patients with type 2 diabetes mellitus, have been proven to reduce major adverse cardiovascular events, including cardiovascular death, in patients with heart failure irrespective of ejection fraction and independently of the hypoglycemic effect. Because of their favorable effects on the kidney and cardiovascular outcomes, their use has been expanded in all patients with any combination of diabetes mellitus type 2, chronic kidney disease and heart failure...
April 27, 2024: Biomedicine & Pharmacotherapy
keyword
keyword
110150
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.